4//SEC Filing
HOUGEN ELIZABETH L 4
Accession 0000874015-25-000060
CIK 0000874015other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 7:40 PM ET
Size
14.8 KB
Accession
0000874015-25-000060
Insider Transaction Report
Form 4
HOUGEN ELIZABETH L
EVP, Finance & CFO
Transactions
- Sale
Common Stock
2025-01-16$32.81/sh−8,870$290,989→ 107,885 total - Award
Performance Restricted Stock Units
2025-01-15+31,000→ 86,635 totalExercise: $0.00From: 2028-01-15→ Common Stock (31,000 underlying) - Award
Restricted Stock Unit
2025-01-15+46,500→ 108,556 totalExercise: $0.00From: 2026-01-15→ Common Stock (46,500 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-01-15−23,887→ 84,669 totalExercise: $0.00From: 2025-01-15→ Common Stock (23,887 underlying) - Exercise/Conversion
Common Stock
2025-01-15+23,887→ 116,755 total
Footnotes (8)
- [F1]Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
- [F2]The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.80 to $32.82 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
- [F4]Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
- [F5]The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.
- [F6]Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
- [F7]Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
- [F8]Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
Documents
Issuer
IONIS PHARMACEUTICALS INC
CIK 0000874015
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001074773
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 7:40 PM ET
- Size
- 14.8 KB